Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 7/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL579703 | 1.00 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL27450020 | 0.84 | CALM1 (0.43) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL580317 | 0.83 | CTSA (0.51) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL587249 | 0.83 | CTSA (0.51) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL580339 | 0.82 | KMT2A (0.46) | CYP1A2CYP3A4CYP2C19MEN1KMT2A | |
| SCHEMBL580382 | 0.82 | KMT2A (0.46) | CYP1A2CYP3A4CYP2C19MEN1KMT2A | |
| SCHEMBL615095 | 0.82 | MAPT (0.46) | TSHRMEN1KMT2ATNFMAPT | |
| SCHEMBL11387106 | 0.81 | MEN1 (0.50) | CYP1A2CYP3A4TSHRCYP2C19MEN1 | |
| SCHEMBL9231158 | 0.81 | LMNA (0.50) | TSHRTNFHTTMAPTNPSR1 | |
| SCHEMBL580171 | 0.81 | TNF (0.49) | CYP1A2CYP3A4CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633695-B1 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | BRIDGE PHARMA INC (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-1633695-A4 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | BRIDGE PHARMA INC (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7141696-B2 | Smooth muscle spasmolytic agents | BRIDGE PHARMA, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1633695-A2 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | Bridge Pharma, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105692-A2 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | BRIDGE PHARMA, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040248987-A1 | Smooth muscle spasmolytic agents | BRIDGE PHARMA, INC. | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248987-A1 | Smooth muscle spasmolytic agents | MYLK, TNNC1, MYLK2 | CYP1A2 426/4885CYP3A4 1373/4885CYP2C9 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.